CGM Linked to More Time in Range
In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.
By
Andrea Surnit
July 14, 2026
Clinical Scorecard: CGM Linked to More Time in Range
At a Glance
Category Detail
Condition Type 2 Diabetes with End-Stage Kidney Failure Key Mechanisms Real-time continuous glucose monitoring improves secondary measures of glycemic control. Target Population Patients aged 18 to 80 years with insulin-treated type 2 diabetes receiving maintenance hemodialysis. Care Setting Dialysis centers
Key Highlights
Real-time continuous glucose monitoring improved time in range from 55% to 63%. Mean glucose levels decreased from 188 mg/dL to 174 mg/dL with continuous monitoring. Time above 180 mg/dL decreased from 44% to 35% with continuous monitoring. No significant difference in time below 70 mg/dL between monitoring strategies. Hyperglycemic episodes remained common in both monitoring periods. Guideline-Based Recommendations
Diagnosis
Management
Use real-time continuous glucose monitoring for improved glycemic control in insulin-treated patients. Monitoring & Follow-up
Monitor glucose levels regularly, with emphasis on time in range and hyperglycemia. Risks
Increased level 1 hypoglycemic episodes during continuous glucose monitoring. Patient & Prescribing Data
Insulin-treated patients with type 2 diabetes on maintenance hemodialysis.
Continuous glucose monitoring may enhance glycemic management.
Clinical Best Practices
Educate patients on sensor trend arrows and glucose patterns. Encourage regular capillary testing alongside continuous monitoring. Related Resources & Content
